• News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • X (Twitter)
  • LinkedIn
Stock Screener·US·Consumer Cyclical·BFNH
Share

BioForce Nanosciences Holdings, Inc. Stocks

$ 7.46Last Updated 13.10.2026

Issuer Rating

2/7
Performance

Modest

Risk

High

Recommendation

Sell

Market Cap

$ 275.10M

$ 7.46
Key Takeaways

Risk factor

Very high price volatility

Data is available to registered users only
Data is available to registered users only

Profitability factor

Greatly overvalued vs peers

Data is available to registered users only
Data is available to registered users only
Sign up to get free access to key risk and return factors, detailed company valuation, and analyst forecasts
Sign up to access all the key risk and return factors

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

About

BioForce Nanosciences Holdings, Inc. (BFNH) specializes in providing natural vitamins, minerals, and a variety of other nutritional supplements, along with powders and beverages, intended for individuals across all age demographics. The firm also operates in the private label market, collaborating with both distributors and production partners. Under its BioForce Eclipse brand, BFNH's dietary supplements reach consumers through a broad network of retailers, including general merchandise stores, sporting goods shops, grocery chains, and large mass merchandisers. Additionally, the company facilitates sales directly via its online presence and telemarketing campaigns. Its corporate base is situated in Virginia Beach, Virginia.

Company Valuation

Greatly overvalued
1/7

From both historical and forecast perspectives, the stock is considerably overpriced compared to similar stocks.

Data is available to registered users only
Sign up to access detailed valuation

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

Trending

15.10.2026 03:57

The index of high-risk stocks has entered a correction: The Russell 2000 has fallen 11% from its peak

15.10.2026 02:42

A "meme" stock favored by Reddit traders hits a 16-month high. Should you buy the stock?

15.10.2026 02:03

Netflix will cut 6% of its workforce amid slowing growth. The company's stock has fallen 40% over the past year

15.10.2026 01:28

S&P 500 and Nasdaq Composite post sharpest one-day drops since July

15.10.2026 00:31

‘Recalibration of expectations’: Chip stocks lose $1 trln in value amid rout

X-channel

Buy

Sell

0 more stocks

Company

  • About
  • Contributors
  • Contacts
  • Legal Information

Social media

  • X (Twitter)
  • LinkedIn

Services

  • Stock Screener
  • Guru Portfolios
  • X (Twitter)
  • LinkedIn
Oninvest© 2026